Boston Scientific (BSX) valuation
Boston Scientific P/E ratio history
Boston Scientific trades at 17.0 times its earnings over the last twelve months and 13.2 times the earnings analysts expect over the next twelve. At its last 9 fiscal year ends its P/E ranged from 13.6 (year to Dec 2019) to 309.9 (year to Dec 2017), with a median of 61.6.
| Fiscal year ended | Price | EPS | P/E | Forward P/E |
|---|---|---|---|---|
| Dec 31, 2025 | $95.35 | $1.94 | 49.2 | 28.4 |
| Dec 31, 2024 | $89.32 | $1.25 | 71.5 | 32.9 |
| Dec 31, 2023 | $57.81 | $1.07 | 54.0 | 26.5 |
| Dec 31, 2022 | $46.27 | $0.45 | 102.8 | 24.5 |
| Dec 31, 2021 | $42.48 | $0.69 | 61.6 | 23.5 |
| Dec 31, 2020 | $35.95 | -$0.08 | n/m | — |
| Dec 31, 2019 | $45.22 | $3.33 | 13.6 | — |
| Dec 31, 2018 | $35.34 | $1.19 | 29.7 | — |
| Dec 31, 2017 | $24.79 | $0.08 | 309.9 | — |
| Dec 31, 2016 | $21.63 | $0.25 | 86.5 | — |
n/m: not meaningful (a loss, or earnings close to zero). The daily P/E line is a chart indicator in the app.
Boston Scientific valuation against its peers
| Company | Market value | P/E | Forward P/E | Price / sales |
|---|---|---|---|---|
| Boston ScientificBSX | $62.4B | 17.0 | 13.2 | 3.0 |
| Becton DickinsonBDX | $54.5B | 74.5 | 15.1 | 2.6 |
| Edwards LifesciencesEW | $53.0B | 52.9 | 28.9 | 8.1 |
| Idexx LaboratoriesIDXX | $43.5B | 38.7 | 34.9 | 9.6 |
| StrykerSYK | $112B | 30.2 | 18.6 | 4.3 |
| GE HealthCareGEHC | $34.6B | 16.2 | 14.3 | 1.6 |
| ResMedRMD | $33.4B | 20.9 | 18.6 | 5.9 |
| MedtronicMDT | $124B | 23.8 | 15.9 | 3.3 |
| DexcomDXCM | $31.1B | 32.4 | 27.3 | 6.1 |
| Peer median | 31.3 | 18.6 | 5.1 |
Reading these multiples
The P/E divides the share price by earnings per share over the last twelve months; the forward P/E divides it by the earnings analysts expect over the next twelve. Price to sales compares the company's market value with its revenue over the last twelve months. A multiple reads differently from one industry to the next, so the peer group above is the fairer comparison.
See also: BSX financials · BSX returns
No forecast, no recommendation. This page describes Boston Scientific from published data; it is not advice to buy, sell or hold any security.
Figures as of the close on Oct 30, 2026 unless a row says otherwise. Prices are split adjusted; returns include dividends reinvested. Data may be delayed. See the disclaimer and how TrendArc works.